CD16-A Activators
CD16-A activators consist of a selection of chemical compounds that indirectly increase the functional activity of CD16-A by acting on various signaling pathways and cellular processes integral to the immune functions in which CD16-A is involved. Phorbol 12-myristate 13-acetate (PMA) and Bryostatin 1, both PKC activators, initiate a cascade of intracellular events that bolster the cytotoxic capabilities of natural killer (NK) cells, which express CD16-A, leading to an enhanced antibody-dependent cellular cytotoxicity (ADCC). Similarly, Ionomycin, by elevating intracellular calcium concentrations, primes NK cells for activation, thereby indirectly promoting CD16-A-mediated immune responses. The heightened ADCC facilitated by CD16-A is further supported by Lenalidomide and Thalidomide, which exert their immunomodulatory influence by amplifying NK cell responsiveness, a critical factor in CD16-A's role in immune surveillance.
The activity of CD16-A is also influenced by small-molecule analogs that mimic the stimulatory effects of cytokines such as Interferon-alpha and Interleukin-2, which are pivotal in the proliferation and activation of NK cells, and consequently, in the upregulation of CD16-A function. Toll-like receptor agonists like CpG Oligodeoxynucleotides and Imiquimod contribute to this activation by engaging innate immune pathways that enhance NK cell-mediated cytotoxicity, integral to CD16-A's function. Additionally, MEK inhibitors such as Cobimetinib and U0126 indirectly influence the activity of CD16-A by modulating signaling pathways within NK cells, which could lead to a more robust ADCC response. Resveratrol, through its broad immunomodulatory effects, is posited to enhance NK cell function, and through this, indirectly upregulate the functional activity of CD16-A. Collectively, these activators, via their targeted cellular and biochemical actions, facilitate the enhancement of CD16-A's role in immune defense mechanisms.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA serves as a diacylglycerol (DAG) analog and activates protein kinase C (PKC), a pathway that upregulates cell signaling involved in the immune response. Enhanced PKC activity can lead to the increased phagocytic ability of natural killer (NK) cells, which express CD16-A, thereby indirectly enhancing its functional activity in ADCC. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels, which is important for NK cell activation. Elevated calcium levels can enhance the cytotoxic function of NK cells, thereby indirectly increasing the activity of CD16-A in mediating the immune response. | ||||||
Bryostatin 1 | 83314-01-6 | sc-201407 | 10 µg | $245.00 | 9 | |
Bryostatin 1 is a PKC activator that, like PMA, can enhance the activation and function of NK cells. This upregulation can lead to an enhanced ADCC response, indirectly increasing the activity of CD16-A. | ||||||
Dexamethasone Sodium Phosphate | 2392-39-4 | sc-204715 sc-204715A | 100 mg 500 mg | $55.00 $158.00 | 7 | |
CpG oligodeoxynucleotides activate toll-like receptor 9 (TLR9), leading to NK cell activation and enhancement of their cytotoxic function, which is dependent on CD16-A activity. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $50.00 $374.00 $2071.00 | 18 | |
Lenalidomide enhances NK cell cytotoxicity by augmenting the immune response, which can indirectly increase the activity of CD16-A on these cells during ADCC. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Thalidomide has immunomodulatory effects that include the activation of NK cells, leading to an enhanced ADCC response and indirect activation of CD16-A. | ||||||
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $67.00 $284.00 | 6 | |
Imiquimod acts as an immune response modifier by activating TLR7, which can lead to NK cell activation and indirectly enhance the function of CD16-A. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
Cobimetinib inhibits MEK, which can lead to the modulation of NK cell activity and indirectly enhance the activity of CD16-A through altered signaling pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2 and can modulate immune cell activity. This modulation may indirectly enhance CD16-A activity by influencing the signaling pathways within NK cells. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol affects various signaling pathways, including those in immune cells. Its immunomodulatory effects could lead to enhanced NK cell function and thus indirectly increase CD16-A activity. | ||||||